Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension

NCT ID: NCT05820880

Last Updated: 2024-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

532 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-06

Study Completion Date

2022-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the efficacy and safety of a fixed-dose combination of perindopril 5 mg /indapamide 1.25 mg / amlodipine 5 mg compared to the free combination of the same components (perindopril 4 mg / indapamide 1.25 mg in a single pill and amlodipine 5 mg pill given separately at the same time) in chinese patients with uncontrolled essential hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fixed [Per/Ind/Aml]

From inclusion to Month 2, patients receive the fixed combination of perindopril 5 mg / indapamide 1.25 mg / amlodipine 5 mg (S06593).

From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg).

From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, for patients who were up-titrated at Month 2 visit: perindopril 10 mg / indapamide 2.5 mg / amlodipine 10 mg or for patients who were not yet up-titrated: perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg.

Group Type EXPERIMENTAL

Fixed [Per/Ind/Aml]

Intervention Type DRUG

Fixed Dose combination of Perindopril/Indapamide/Amlodipine

Free [Per/Ind + Aml]

From inclusion to Month 2, patients receive the free combination of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg.

From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg for patients).

From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie for patients who were up-titrated at Month 2 visit: double dose of perindopril 4 mg / indapamide 1.25 mg plus double dose of amlodipine 5 mg or for patients who were not yet up-titrated:double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg.

Group Type ACTIVE_COMPARATOR

Free [Per/Ind + Aml]

Intervention Type DRUG

Free dose combination of Perindopril/Indapamide and Amlodipine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fixed [Per/Ind/Aml]

Fixed Dose combination of Perindopril/Indapamide/Amlodipine

Intervention Type DRUG

Free [Per/Ind + Aml]

Free dose combination of Perindopril/Indapamide and Amlodipine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women of Asian origin
* ≥18 years old
* Treated for essential hypertension
* Having the day of the selection visit an uncontrolled hypertension treated with any anti-hypertensive monotherapy at maximal dose or any dual therapy at starting dose according to investigator's routine practice or at least 1 month prior to the visit
* Having at the selection visit a sitting SBP≥140 and \<180 mmHg and DBP≥90 and \<110 mmHg

Exclusion Criteria

* Known or suspected symptomatic orthostatic hypotension or positive orthostatic test at the selection visit
* Treatment with more than 2 antihypertensive drugs or with 2 antihypertensive drugs at the highest doses at the selection visit
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut de Recherches Internationales Servier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Site Status

Xuanwu Hospital Capital Medical Universtiy

Beijing, Beijing Municipality, China

Site Status

The First affiliated hospital Chongqing Medical University

Chongqing, Chongqing Municipality, China

Site Status

The second affiliated hospital of Chongqing medical university

Chongqing, Chongqing Municipality, China

Site Status

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Site Status

The first affiliated hospital of Fujian medical university

Fuzhou, Fujian, China

Site Status

Lanzhou University Second Hospital

Lanzhou, Gansu, China

Site Status

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Site Status

The First affiliated hospital of Harbin Medical University

Harbin, Heilongjiang, China

Site Status

The First affiliated hospital of Zhengzhou University

Zhengzhou, Henan, China

Site Status

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Site Status

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Site Status

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Site Status

Xiangya Hospital of Central South University

Changsha, Hunan, China

Site Status

The First Affiliated Hosptial of Baotou Medical college, Innter Mongolia University of Science & Technology

Baotou, Inner Mongolia, China

Site Status

Inner Mongolia People's Hospital

Hohhot, Inner Mongolia, China

Site Status

The Affiliated Hospital of Xuzhou Medical College

Xuzhou, Jiangshu, China

Site Status

Xuzhou Central Hospital

Xuzhou, Jiangshu, China

Site Status

The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status

Wuxi Second People's Hospital

Wuxi, Jiangsu, China

Site Status

Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, China

Site Status

Yangzhou First People's Hospital

Yangzhou, Jiangsu, China

Site Status

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

Site Status

The First affiliated hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

The Second affiliated hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

Jilin university China-Japan Union Hospital

Changchun, Jilin, China

Site Status

The First Bethune Hospital of Jilin University

Changchun, Jilin, China

Site Status

Daqing Oilfield general hospital

Daqing, Liaonig, China

Site Status

First affiliated hospital of Dalian medical university

Dalian, Liaoning, China

Site Status

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Site Status

The People's Hospital of Liaoning Province

Shenyang, Liaoning, China

Site Status

The Affiliated Jiangning Hospital of Nanjing Medical University

Nanjing, Nanjing, China

Site Status

Qinghai Provincial People's Hospital

Xining, Qinghai, China

Site Status

Shandong Provincial Qianfoshan Hospita

Jinan, Shandong, China

Site Status

Linyi People's Hospital

Linyi, Shandong, China

Site Status

Zaozhuang Municipal Hospital

Zaozhuang, Shandong, China

Site Status

Ruijin Hospital affiliated to Shanghai Jiaotong University

Shanghai, Shanghai Municipality, China

Site Status

The First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Site Status

The First Affiliated Hospital, School of Medicine of Xi'an Jiaotong University

Xi’an, Shanxi, China

Site Status

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Site Status

Tianjin People's hospital

Tianjin, Tianjin Municipality, China

Site Status

People's Hospital of Xinjiang Uyghur Autonomous Region

Ürümqi, Uyghur Autonomous Region, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Wang JG, Topouchian J, Bricout-Hennel S, Mu J, Chen L, Li P, He S, Luo S, Jiang W, Jiang Y, Sun Y, Zhang Y, Asmar R. Efficacy and safety of a single-pill versus free combination of perindopril/indapamide/amlodipine: a multicenter, randomized, double-blind study in Chinese patients with hypertension. J Hypertens. 2024 Aug 1;42(8):1373-1381. doi: 10.1097/HJH.0000000000003741. Epub 2024 Apr 24.

Reference Type BACKGROUND
PMID: 38660708 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CL3-6593-018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Add-on to Micamlo BP Trial
NCT01975246 COMPLETED PHASE3